脂多糖与非酒精性脂肪性肝病治疗

Lipopolysaccharide and nonalcoholic fatty liver disease treatment

摘要:

非酒精性脂肪性肝病（NAFLD）是中国乃至全世界最常见的肝病类型之一，目前NAFLD发病率在全球范围内呈上升趋势，是全球慢性肝硬化最重要且最常见的病因，给全球带来了极大的医疗负担，且仍没有针对其的有效治疗措施。近年来，大量针对NAFLD的药物治疗研究正在进行，分别通过干预与脂多糖（LPS）相关的法尼酯X受体、Toll样受体4、核因子-κB等主要信号通路对肝损伤进行保护，还通过调节肠道菌群的组成和恢复肠道屏障功能、抑制LPS诱导的细胞及其相关因子表达，从而达到治疗NAFLD的效果。该文综述以LPS为NAFLD治疗靶点的最新研究进展，旨在为临床治疗NAFLD提供参考。

Abstract:

Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the most prevalent hepatic disorders in China and the world. Currently, NAFLD is on the rise globally and represents the most significant and prevalent cause of chronic liver cirrhosis ,imposing a substantial medical burden worldwide. There are still no effective treatments available for NAFLD. In recent years, numerous studies on drug treatment for NAFLD has been undertaken, which focuses on protecting liver injury by intervening in major signaling pathways related to lipopolysaccharide (LPS), including farnesoid X receptor, Toll-like receptor 4 and nuclear factor-kappa Additionally, therapeutic effects are also achieved by modulating gut microbiota composition, restoring intestinal barrier integrity, and suppressing the activation of LPS-induced inflammatory cells and associated mediators，ultimately achieving therapeutic effects against NAFLD. This article comprehensively reviews the latest advancements in targeting LPS for NAFLD treatment, aiming to provide evidence-based references for clinical management of NAFLD.